Glucodynamics and glucocracy in type 2 diabetes mellitus: clinical evidence and practice-based opinion on modern sulfonylurea use, from an International Expert Group (South Asia, Middle East & Africa) via modified Delphi method

References

• IDF Diabetes Atlas, Ninth Edition. International diabetes federation [Internet]; 2019. Available from: https://www.diabetesatlas.org/en/resources/.
   Google Scholar
• Thibault V, Bélanger M, LeBlanc E, et al. Factors that could explain the increasing prevalence of type 2 diabetes among adults in a Canadian province: a critical review and analysis. Diabetol Metab Syndr. 2016;8(1):71.
   PubMed Web of Science ®Google Scholar
• Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, et al. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7(17):354–395.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701.
   PubMed Web of Science ®Google Scholar
• Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne). 2017;8:6.
   PubMed Web of Science ®Google Scholar
• Kalra S, Das AK, Baruah MP, et al. Glucocrinology of modern sulfonylureas: clinical evidence and practice-based opinion from an International Expert Group. Diabetes Ther. 2019;10(5):1577–1593.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic targets: Standards of medical care in diabetes—2018. Dia Care. 2018;41(Supplement 1):S55–S64.
   PubMed Web of Science ®Google Scholar
• de Villiers MR, de Villiers PJT, Kent AP. The Delphi technique in health sciences education research. Med Teach. 2005;27(7):639–643.
   PubMed Web of Science ®Google Scholar
• Green RA. The Delphi technique in educational research. SAGE Open. 2014;4(2):215824401452977.
   Google Scholar
• Hirst JA, Farmer AJ, Dyar A, et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia. 2013;56(5):973–984.
   PubMed Web of Science ®Google Scholar
• Kudaravalli J, Vijayalakshmi G, Kiran Kishore K. Safety and efficacy of sulfonylurea drugs in type 2 diabetes mellitus. Apollo Med. 2013;10(2):165–168.
   Google Scholar
• Devarajan T, Venkataraman S, Kandasamy N, et al. Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: Indian multicentric randomized trial – START Study. Indian J Endocrinol Metab. 2017;21(5):745–750.
   PubMedGoogle Scholar
• Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Dia Care. 2011;34(9):2015–2022.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMohan S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
   PubMed Web of Science ®Google Scholar
• Kalra S, Bahendeka S, Sahay R, et al. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes Mellitus – International Task Force. Indian J Endocrinol Metab. 2018;22(1):132–157.
   PubMedGoogle Scholar
• Rosenstock J, Kahn SE, Johansen OE, for the CAROLINA Investigators, et al. Effect of linagliptin vs. glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155.
   PubMed Web of Science ®Google Scholar
• Sola D, Rossi L, Schianca GPC, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840–848.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34(8):535–542.
   PubMed Web of Science ®Google Scholar
• Landman GWD, de Bock GH, van Hateren KJJ, et al. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. Letizia Hribal M, editor. PLOS ONE. 2014;9(2):e82880.
   PubMed Web of Science ®Google Scholar
• Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabet Endocrinol. 2017;5(11):887–897.
   PubMed Web of Science ®Google Scholar
• Kim H, Kim D, Cha B, et al. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: a randomized, open label, parallel group, multicenter study in Korea. J Diabetes Invest. 2014;5(6):701–708.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hong J, Chi J, et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas – a meta-analysis from randomized clinical trials: dipeptidyl peptidase-IV Inhibitors versus sulfonylureas. Diabetes Metab Res Rev. 2014;30(3):241–256.
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Bugos C, Austin M, Atherton T, et al. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabet Res Clin Prac. 2000;50:47.
   PubMed Web of Science ®Google Scholar
• Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). Vasc Health Risk Manag. 2012;8:463–472.
   PubMedGoogle Scholar
• Weitgasser R, Lechleitner M, Luger A, et al. Effects of glimepiride on HbA1c and body weight in type 2 diabetes: results of a 1.5-year follow-up study. Diabet Res Clin Prac. 2003;61(1):13–19.
   PubMed Web of Science ®Google Scholar
• Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014;10:319–326.
   PubMedGoogle Scholar
• American Diabetes Association. Standards of medical care in diabetes—2019 abridged for primary care providers. Clin Diabetes. 2019;37(1):11–34.
   PubMedGoogle Scholar
• Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J. 1999;138(5 Pt 1):S346–S352.
   PubMed Web of Science ®Google Scholar
• Sadikot SM, Mogensen CE. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract. 2008;82(3):391–395.
   PubMed Web of Science ®Google Scholar
• Chow CK, Ramasundarahettige C, Hu W, PURE investigators, et al. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Lancet Diabet Endocrinol. 2018;6(10):798–808.
   PubMed Web of Science ®Google Scholar
• Singh K, Narayan KMV, Eggleston K. Economic impact of diabetes in South Asia: the magnitude of the problem. Curr Diab Rep. 2019;19(6):34.
   PubMed Web of Science ®Google Scholar
• Klarenbach S, Cameron C, Singh S, et al. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ. 2011;183(16):E1213–E1220.
   PubMed Web of Science ®Google Scholar
• Zhang Y, McCoy RG, Mason JE, et al. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care . 2014;37(5):1338–1345.
   PubMed Web of Science ®Google Scholar
• Naidoo P, Rambiritch V, Butkow N, et al. Optimal utilisation of sulphonylureas in resource-constrained settings. Cardiovasc J Afr. 2014;25(2):83–85.
   PubMed Web of Science ®Google Scholar
• Schnell O, Standl E, Catrinoiu D, et al. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2019;18(1):30.
   PubMed Web of Science ®Google Scholar
• Rastogi A, Bhansali A. SGLT2 inhibitors through the windows of EMPA-REG and CANVAS Trials: a review. Diabetes Ther. 2017;8(6):1245–1251.
   PubMed Web of Science ®Google Scholar
• Kim MK, Ko SH, Kim BY, Committee of Clinical Practice Guidelines, Korean Diabetes Association, et al. 2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 2019;43(4):398–406.
   PubMed Web of Science ®Google Scholar
• Wittbrodt ET, Eudicone JM, Bell KF, et al. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018;24(8 Suppl):S146–S155.
   PubMed Web of Science ®Google Scholar
• Gomes MB, Rathmann W, Charbonnel B, DISCOVER investigators, et al. Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. Diabetes Res Clin Pract. 2019;151:20–32.
   PubMed Web of Science ®Google Scholar